Cefotiam

Cefotiam

SCHEMBL149538

CN(C)CCn1nnnc1SCC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)Cc3csc(N)n3)[C@H]2SC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

dacAdacBdacCftsImrcAmrcBmrdA

The experimentally established mechanism targets of Cefotiam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 8/20 1.00
LMNA P02545 3/20 1.00
HSD17B10 Q99714 2/20 1.00
L3MBTL1 Q9Y468 1/20 0.99
NR1I2 O75469 3/20 0.58
PGR P06401 3/20 0.58
KDM4E B2RXH2 1/20 0.58
MEN1 O00255 1/20 0.58
KMT2A Q03164 1/20 0.58
POLB P06746 9/20 0.55
MAPT P10636 7/20 0.55
SMN1; SMN2 Q16637 1/20 0.52
SLC22A6 Q4U2R8 3/20 0.51
SLC22A8 Q8TCC7 3/20 0.51
SLC22A11 Q9NSA0 3/20 0.51
PPARG P37231 2/20 0.51
CTDSP1 Q9GZU7 2/20 0.51
ALDH1A1 P00352 3/20 0.51
SLC6A4 P31645 1/20 0.50
DAO P14920 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cefotiam SCHEMBL6019446 1.00 TDP1 (1.00) TDP1LMNAHSD17B10L3MBTL1NR1I2
Cefotiam SCHEMBL11095123 1.00 TDP1 (1.00) TDP1LMNAHSD17B10L3MBTL1NR1I2
Cefotiam SCHEMBL16473046 1.00 TDP1 (1.00) TDP1LMNAHSD17B10L3MBTL1NR1I2
Cefotiam SCHEMBL9754126 1.00 TDP1 (1.00) TDP1LMNAHSD17B10L3MBTL1NR1I2
Cefotiam SCHEMBL9754124 1.00 TDP1 (1.00) TDP1LMNAHSD17B10L3MBTL1NR1I2
Cefotiam SCHEMBL65480 0.99 L3MBTL1 (1.00) TDP1LMNAHSD17B10L3MBTL1NR1I2
Cefotiam SCHEMBL11065530 0.99 L3MBTL1 (1.00) TDP1LMNAHSD17B10L3MBTL1NR1I2
Cefotiam SCHEMBL27767071 0.99 TDP1 (0.99) TDP1LMNAHSD17B10L3MBTL1NR1I2
Cefotiam SCHEMBL193845 0.99 L3MBTL1 (1.00) TDP1LMNAHSD17B10L3MBTL1NR1I2
Cefotiam SCHEMBL10899868 0.99 L3MBTL1 (1.00) TDP1LMNAHSD17B10L3MBTL1NR1I2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 9469 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12637481-B2 Boronic acid derivatives and therapeutic uses thereof QPEX BIOPHARMA, INC. (US) 2026-05-26 US claimed
CN-122080024-A Cefatigure Synthesis method of An 2026-05-26 CN claimed
US-20260108619-A1 CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS HANGZHOU DAC BIOTECH CO., LTD. (CN) 2026-04-23 US claimed
US-12590108-B2 Boracic acid compound PHAENO THERAPEUTICS CO., LTD (CN) 2026-03-31 US claimed
US-12576124-B2 Formulation of a conjugate of a tubulysin analog to a cell-binding molecule HANGZHOU DAC BIOTECH CO., LTD (CN) 2026-03-17 US claimed
US-12529704-B2 Methods for objective assessment of stress, early detection of risk for stress disorders, matching individuals with treatments, monitoring response to treatment, and new methods of use for drugs INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2026-01-20 US claimed
WO-2025237916-A1 BIOMATERIAL COMPOSITION COMPRISING A POLYHYDROXYBUTYRATE IN PARTICULATE FORM LABORATOIRES VIVACY (FR) 2025-11-20 WO claimed
US-20250339551-A1 AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE DIFFERENT FUNCTIONAL SMALL MOLECULES FOR ENHANCED TREATMENT OF REFRACTORY DISEASES HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) 2025-11-06 US claimed
EP-4642492-A1 AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES Hangzhou Seehe Biotechnology Co., Ltd (CN) 2025-11-05 EP claimed
EP-4642484-A1 TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE Hangzhou Seehe Biotechnology Co., Ltd (CN) 2025-11-05 EP claimed
EP-0138523-A1 Penicillin derivatives and process for preparing the same (11111) TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) 1985-04-24 EP claimed
EP-0026746-B1 COMBINATORY COMPOSITIONS FOR USE IN A METHOD FOR ENHANCING THE ACTIVITY OF ANTIBIOTICS, ANTIBIOTIC PREPARATIONS HAVING ENHANCED ACTIVITY AND PROCESS FOR THEIR PRODUCTION CIBA-GEIGY AG (CH) 1985-04-10 EP claimed
US-4503040-A 6-(Aminoacyloxymethyl)penicillanic acid 1,1-dioxides as beta-lactamase inhibitors PFIZER INC. (US) 1985-03-05 US claimed
US-4414204-A WITH A MURAMYL-PEPTIDE CIBA-GEIGY CORPORATION (US) 1983-11-08 US claimed
US-4409209-A POTENTIATION OF ANTIBIOTICS CIBA-GEIGY CORPORATION (US) 1983-10-11 US claimed
EP-0056560-A1 Active antibiotic compositions, process for their manufacture and process for the antibiotic activity of antibiotics CIBA-GEIGY AG (CH) 1982-07-28 EP claimed
EP-0050965-A1 Beta-lactamase inhibitory composition Takeda Chemical Industries, Ltd. (JP) 1982-05-05 EP claimed
EP-0004925-B1 SYNERGISTIC MIXTURES OF ANTIBIOTICS AND PROCESS FOR THEIR PRODUCTION CIBA-GEIGY AG (CH) 1982-02-24 EP claimed
EP-0033241-A2 Pharmaceutical compositions for rectal administration Takeda Chemical Industries, Ltd. (JP) 1981-08-05 EP claimed
EP-0004925-A1 Synergistic mixtures of antibiotics and process for their production CIBA-GEIGY AG (CH) 1979-10-31 EP claimed